➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Dow
Express Scripts
AstraZeneca
Mallinckrodt

Last Updated: November 28, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,071,977

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,071,977
Title:Highly purifid pharmaceutical grade tasimelteon
Abstract: A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
Inventor(s): Phadke; Deepak (Olathe, KS), Platt; Natalie M (Columbia, MD), Pandrapragada; Ravi K (Clarksburg, MD)
Assignee: VANDA PHARMACEUTICALS INC. (Washington, DC)
Application Number:15/117,734
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,071,977
Patent Claims: 1. A process for synthesizing highly purified, pharmaceutical grade tasimelteon, the process comprising: (a) propionylating ((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methanamine or a salt thereof to yield tasimelteon; (b) crystallizing the tasimelteon produced in step (a); (c) assaying the crystallized tasimelteon from step (b) for the presence of one or both of Impurity 5 (N-((2-(2,3-dihydrobenzofuran-4-yl)-1-((2-(2,3-dihydrobenzofuran-4-yl)cyc- lopropyl)(propionamido)methyl) cyclopropyl)methyl)propionamide) and Impurity 6 (2-hydroxy-6-(2-(propionamidomethyl)cyclopropyl)phenethyl 2-(2-hydroxyethyl)-3-(2-(propionamidomethyl)cyclopropyl)phenyl carbonate); and (d)(i) if the crystallized tasimelteon meets pre-set specifications for Impurity 5 or Impurity 6, or both, then collecting the highly purified, pharmaceutical grade tasimelteon; or (d)(ii) if the crystallized tasimelteon fails to meet pre-set specifications for Impurity 5 or Impurity 6, or both, then further purifying the tasimelteon and repeating steps (c) and (d), or discarding the batch.

2. The process of claim 1, wherein the propionylating step comprises contacting ((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methanamine or a salt thereof with a propionyl halide, a propionyl anhydride, a propionyl ester, a propionyl amide, a propionyl imidazolide, or with propionic acid and a dehydrating agent or the product thereof.

3. The process of claim 1, wherein the propionylating step comprises contacting ((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methanamine or a salt thereof with a propionyl halide, a propionyl anhydride, a propionyl ester, a propionyl amide, a propionyl imidazolide, or with propionic acid and a dehydrating agent or the product thereof in the presence of an organic solvent.

4. The process of claim 3, wherein the propionylating step comprises contacting ((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methanamine or a salt thereof with propionyl chloride in the presence of an organic solvent and an aqueous base.

5. The process of claim 4, wherein the organic solvent comprises tert-butyl methyl ether (TBME) and the aqueous base comprises NaOH.

6. The process of claim 3, wherein the ((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methanamine or a salt thereof is Intermediate 5 (((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methanaminium chloride) and wherein after the propionylation step and before the crystallizing step, the mixture of tasimelteon is assayed for the presence of Intermediate 5 and, if the mixture does not meet pre-set specifications for Intermediate 5, then repeating step (a) or discarding the mixture.

7. The process of claim 3, wherein after the propionylation step and before the crystallizing step, the mixture of tasimelteon is washed with aqueous base and the aqueous layer is discarded.

8. The process of claim 7, wherein the washed mixture is distilled and the distillate is discarded.

9. The process of claim 8, wherein the distilling step is carried out in ethanol at a pot temperature of up to about 58.degree. C. and a pressure of less than about 100 mmHg.

10. The process of claim 1, wherein the crystallization step comprises dissolving the tasimelteon by stirring and warming a mixture of the tasimelteon and a C1-C4 alkanol.

11. The process of claim 10, wherein the mixture of C1-C4 alkanol and tasimelteon is warmed to about 35 to 40.degree. C. while stirring and then cooled to about 13 to 17.degree. C. while stirring.

12. The process of claim 1, wherein the crystallization step optionally comprises seeding.

13. The process of claim 1, wherein the assaying step is carried out by HPLC.

14. The process of claim 1, wherein the pre-set specifications for the one or both of Impurity 5 and Impurity 6 are each not more than 0.15% (Area/Area).

15. The process of claim 1, wherein the further purifying comprises recrystallizing the tasimelteon.

16. The process of claim 1, wherein a particle size of crystals collected in step (d) is reduced to meet particle size specifications for pharmaceutical grade tasimelteon.

17. The process of claim 16, wherein crystals that meet particle size specifications for pharmaceutical grade tasimelteon are admixed with one or more excipients to prepare a pharmaceutical composition comprising pharmaceutical grade tasimelteon.

18. A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon, the process comprising: (a) analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more of: N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)-3-- methylbutanamide (Impurity 1), N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)-pentanamide (Impurity 2), 1,3-Bis(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)urea (Impurity 3), N-(((1R,2R)-2-(benzofuran-4-yl)cyclopropyl)methyl)propionamide (Impurity 4), N-((2-(2,3-dihydrobenzofuran-4-yl)-1-((2-(2,3-dihydrobenzofuran-4-yl)- cyclopropyl) (propionamido)methyl) cyclopropyl)methyl)propionamide (Impurity 5), 2-hydroxy-6-(2-(propionamidomethyl)cyclopropyl)phenethyl 2-(2-hydroxyethyl)-3-(2-(propionamidomethyl)cyclopropyl)phenyl carbonate (Impurity 6), or N-(((1R,2R)-2-(3-Oxo-2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl) propionamide (Impurity 7); and (b) if the batch meets pre-set specifications for the amount of the one or more of Impurity 1, Impurity 2, Impurity 3, Impurity 4, Impurity 5, Impurity 6, or Impurity 7, then continuing to process the tasimelteon to prepare bulk tasimelteon drug substance for formulation; or (c) if the tasimelteon does not meet said pre-set specifications, then further purifying the tasimelteon and repeating steps (a) and (b) or discarding the batch.

19. The process of claim 18 wherein the pre-set specifications for each of the one or more impurities is NMT 0.15 wt %.

20. The process of claim 18 wherein further pre-set specifications for continuing to process the tasimelteon comprise that the tasimelteon is NLT 95.0% pure by area.

21. The process of claim 20 wherein further pre-set specifications for continuing to process the tasimelteon include that the amount of any other single impurity is NMT 0.10 area %.

22. A process for preparing a batch of highly purified tasimelteon that comprises: (a) synthesizing a batch of tasimelteon in crystalline form; (b) analyzing the batch for the presence of one or more of N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)-3-methylbut- anamide (Impurity 1), N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)-pentanamide (Impurity 2), 1,3-Bis(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)urea (Impurity 3), N-(((1R,2R)-2-(benzofuran-4-yl)cyclopropyl)methyl)propionamide (Impurity 4), N-((2-(2,3-dihydrobenzofuran-4-yl)-1-((2-(2,3-dihydrobenzofuran-4-yl)- cyclopropyl) (propionamido)methyl) cyclopropyl)methyl)propionamide (Impurity 5), 2-hydroxy-6-(2-(propionamidomethyl)cyclopropyl)phenethyl 2-(2-hydroxyethyl)-3-(2-(propionamidomethyl)cyclopropyl)phenyl carbonate (Impurity 6), or N-(((1R,2R)-2-(3-Oxo-2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)propio- namide (Impurity 7); (c) if the batch of tasimelteon comprises: (i) NMT 0.15 wt % of the one or more of Impurities 1-7; and (ii) the batch comprises no more than 0.10 wt % of any single unidentified impurity, then; (d) milling the tasimelteon to meet particle size specifications; or (e) if the batch of tasimelteon does not meet the purity specifications recited in (c)(i) and (ii), recrystallizing and reanalyzing the batch of tasimelteon.

23. A batch of tasimelteon for use in preparing a pharmaceutical composition for human use, wherein the batch of tasimelteon comprises: tasimelteon that is at least 98.0 area % pure and that has been analyzed and shown to comprise no more than 0.15 wt % each of one or more impurities selected from a group consisting of: N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)-3-methylbut- anamide (Impurity 1), N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)-pentanamide (Impurity 2), 1,3-Bis(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)urea (Impurity 3), N-(((1R,2R)-2-(benzofuran-4-yl)cyclopropyl)methyl)propionamide (Impurity 4), N-((2-(2,3-dihydrobenzofuran-4-yl)-1-((2-(2,3-dihydrobenzofuran-4-yl)- cyclopropyl) (propionamido)methyl) cyclopropyl)methyl)propionamide (Impurity 5), 2-hydroxy-6-(2-(propionamidomethyl)cyclopropyl)phenethyl 2-(2-hydroxyethyl)-3-(2-(propionamidomethyl)cyclopropyl)phenyl carbonate (Impurity 6), and N-(((1R,2R)-2-(3-Oxo-2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)propio- namide (Impurity 7).

24. Purified tasimelteon wherein the tasimelteon does not contain any of the following impurities at a concentration greater than about 0.15%: N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)-3-methylbut- anamide (Impurity 1), N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)-pentanamide (Impurity 2), 1,3-Bis(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)urea (Impurity 3), N-(((1R,2R)-2-(benzofuran-4-yl)cyclopropyl)methyl)propionamide (Impurity 4), N-((2-(2,3-dihydrobenzofuran-4-yl)-1-((2-(2,3-dihydrobenzofuran-4-yl)- cyclopropyl) (propionamido)methyl) cyclopropyl)methyl)propionamide (Impurity 5), 2-hydroxy-6-(2-(propionamidomethyl)cyclopropyl)phenethyl 2-(2-hydroxyethyl)-3-(2-(propionamidomethyl)cyclopropyl)phenyl carbonate (Impurity 6), or N-(((1R,2R)-2-(3-Oxo-2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl) propionamide (Impurity 7).

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
McKesson
AstraZeneca
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.